HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas.

AbstractINTRODUCTION:
conjunctival melanomas have high local relapse rates. Oncologic and visual outcomes can be improved with proton therapy and no-touch surgery.
MATERIAL AND METHODS:
a monocentric retrospective study of consecutive patients treated with surgery and proton therapy for conjunctival melanoma was conducted. Proton therapy was performed to a total dose of 45 Grays physical dose delivered in eight fractions over two weeks.
RESULTS:
Ninety-two patients were included. The mean age was 63-year-old. 65.2% of patients had primary acquired melanosis. The mean tumor thickness and diameter was 2.5 mm and 7.0 mm respectively. The clinical stage was T1 in 71.6% of cases, with a quadrangular involvement of more than 90° in 69% of cases. Conjunctival melanomas were of epithelioid cell-type in 40% of cases. Mean follow-up was 4.7 years. Five-year local failure rate was 33.2%. Of 25 local recurrences, 14 were marginal/out-of-field, 4 in-field, others were undetermined. First surgery at expert center resulted in 24.3% of local failure at 5 years versus 38.7% if performed elsewhere (p = 0.41). Salvage exenteration was performed in 13 patients. Tumor stage and quadrangular involvement were significant factors for local failure. Five-year progression-free survival and cause-specific death rates were 61.5 and 3.6%. Stage and epithelioid type were associated with poorer progression-free survival. Trophic toxicity occurred in 22.9% of patients and was treated locally, with grafts in 7 patients. Glaucoma and cataract occurred in 13 and 22 patients respectively. Prognostic factors for visual deterioration were age, tumor extent (multifocality, quadrangular involvement > 180°) and cryotherapy.
CONCLUSIONS:
5-year local failure rate after postoperative proton therapy for conjunctival melanoma was of 33.2%. Radiation-induced complications were overall manageable.
AuthorsJuliette Thariat, Julia Salleron, Celia Maschi, Edouard Fevrier, Sandra Lassalle, Lauris Gastaud, Stephanie Baillif, Audrey Claren, Florent Baumard, Joel Herault, Jean Pierre Caujolle
JournalRadiation oncology (London, England) (Radiat Oncol) Vol. 14 Issue 1 Pg. 239 (Dec 27 2019) ISSN: 1748-717X [Electronic] England
PMID31881977 (Publication Type: Journal Article)
Topics
  • Aged
  • Conjunctival Neoplasms (mortality, pathology, radiotherapy)
  • Female
  • Humans
  • Male
  • Melanoma (mortality, pathology, radiotherapy)
  • Middle Aged
  • Neoplasm Recurrence, Local (mortality, pathology, radiotherapy)
  • Postoperative Care
  • Prognosis
  • Proton Therapy (mortality)
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: